- Home
- UAMY vs MURA Comparison
UAMY vs MURA Comparison
Compare UAMY & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- MURA
- Stock Information
- Founded
- UAMY 1968
- MURA 2013
- Country
- UAMY United States
- MURA Ireland
- Employees
- UAMY N/A
- MURA N/A
- Industry
- UAMY Metal Fabrications
- MURA
- Sector
- UAMY Industrials
- MURA
- Exchange
- UAMY Nasdaq
- MURA Nasdaq
- Market Cap
- UAMY 74.2M
- MURA 62.2M
- IPO Year
- UAMY N/A
- MURA N/A
- Fundamental
- Price
- UAMY $0.52
- MURA $3.45
- Analyst Decision
- UAMY
- MURA Strong Buy
- Analyst Count
- UAMY 0
- MURA 4
- Target Price
- UAMY N/A
- MURA $16.00
- AVG Volume (30 Days)
- UAMY 495.6K
- MURA 56.9K
- Earning Date
- UAMY 11-12-2024
- MURA 11-13-2024
- Dividend Yield
- UAMY N/A
- MURA N/A
- EPS Growth
- UAMY N/A
- MURA N/A
- EPS
- UAMY N/A
- MURA N/A
- Revenue
- UAMY $9,969,893.00
- MURA N/A
- Revenue This Year
- UAMY N/A
- MURA N/A
- Revenue Next Year
- UAMY N/A
- MURA N/A
- P/E Ratio
- UAMY N/A
- MURA N/A
- Revenue Growth
- UAMY 21.44
- MURA N/A
- 52 Week Low
- UAMY $0.17
- MURA $2.88
- 52 Week High
- UAMY $0.82
- MURA $6.25
- Technical
- Relative Strength Index (RSI)
- UAMY 31.15
- MURA 48.79
- Support Level
- UAMY $0.60
- MURA $3.31
- Resistance Level
- UAMY $0.71
- MURA $3.66
- Average True Range (ATR)
- UAMY 0.05
- MURA 0.18
- MACD
- UAMY -0.01
- MURA -0.01
- Stochastic Oscillator
- UAMY 10.79
- MURA 45.45
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.